How we diagnose and treat hereditary transthyretin-mediated amyloidosis with polyneuropathy in the Balkan region: an expert opinion.

Ivailo Tournev, Janez Zidar, Borut Peterlin, Ervina Bilić, Stojan Perić, Sonja Pavlović, Teodora Chamova

Abstract read

In one paragraph

Article in Frontiers in neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ivailo TournevClinic of Nervous Diseases at Aleksandrovska University Hospital; Department of Neurology, Medical University - Sofia, Sofia, Bulgaria.

Janez ZidarInstitute of Clinical Neurophysiology, Division of Neurology, University Medical Centre, Ljubljana, Slovenia.

Borut PeterlinClinical Institute of Genomic Medicine Ljubljana, Ljubljana, Slovenia.

Ervina BilićDepartment of Neurology Clinical Hospital Center Zagreb, University of Zagreb School of Medicine Zagreb, Zagreb, Croatia.

Stojan PerićFaculty of Medicine, University of Belgrade, Belgrade, Serbia.

Sonja PavlovićLaboratory for Molecular Hematology, Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.

Teodora ChamovaClinic of Nervous Diseases at Aleksandrovska University Hospital; Department of Neurology, Medical University - Sofia, Sofia, Bulgaria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hereditary transthyretin-mediated (ATTRV; v, variant) amyloidosis is a genetic disorder that causes abnormal accumulation of amyloid deposits in organs and tissues. The most common neurological manifestation is polyneuropathy (PN) of the autonomic nervous system, cardiac involvement and average survival of 6-12 years since onset of symptoms. Recent years have been marked by advancements in diagnosis and management of ATTRv amyloidosis with PN. In Balkan countries, endemic regions for some

Indexed as

Balkan regiondisease managementexpert opinionhereditary transthyretin-mediated amyloidosispatient journey

Identifiers

PMID42434077

DOI10.3389/fneur.2026.1876381

PMCPMC13352523

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.